发明申请
US20130040996A1 COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF
审中-公开
用于治疗甲状腺功能亢进的组合物及其制备方法
- 专利标题： COMPOSITION FOR TREATING ATHEROSCLEROSIS AND A PREPARATION METHOD THEREOF
- 专利标题（中）： 用于治疗甲状腺功能亢进的组合物及其制备方法
-
申请号： US13570963申请日： 2012-08-09
-
公开(公告)号： US20130040996A1公开(公告)日： 2013-02-14
- 发明人: YANG-CHANG WU , FANG-RONG CHANG , TUSTY-JIUAN HSIEH , SUH-HANG JUO , AN-SHEN LIN , YING-CHI DU
- 申请人： YANG-CHANG WU , FANG-RONG CHANG , TUSTY-JIUAN HSIEH , SUH-HANG JUO , AN-SHEN LIN , YING-CHI DU
- 申请人地址： TW KAOHSIUNG CITY
- 专利权人： KAOHSIUNG MEDICAL UNIVERSITY
- 当前专利权人： KAOHSIUNG MEDICAL UNIVERSITY
- 当前专利权人地址： TW KAOHSIUNG CITY
- 优先权： TW100128614 20110810
- 主分类号： A61K31/12
- IPC分类号： A61K31/12 ; C07C49/835 ; A61K31/353 ; A61K31/4439 ; A61P9/10 ; C07C49/84 ; A61P29/00
摘要：
Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4′-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPARγ inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPARγ ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1β (IL-1β) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).
信息查询
